New hope for rare dementia that steals language

This study is testing an experimental drug called NS101 for people with semantic variant primary progressive aphasia (svPPA), a rare type of dementia that primarily affects language. Fifteen participants will receive either the drug or a placebo through intravenous infusions to see if it's safe and if it shows any early signs of helping. The main goal is to check for side effects and see how the drug behaves in the body, with a secondary look at whether it might slow the disease.